Reduction of leptin levels by four cardiac hormones: Implications for hypertension in obesity

Lane,Meghan  L.; Vesely,David  L.

doi:10.3892/etm.2013.1173

Reduction of leptin levels by four cardiac hormones: Implications for hypertension in obesity

Authors:
- Meghan L. Lane
- David L. Vesely
View Affiliations

Affiliations: Departments of Medicine, Molecular Pharmacology and Physiology, and James A. Haley VA Medical Center, University of South Florida Morsani School of Medicine, Tampa, FL 33612, USA
Published online on: June 21, 2013 https://doi.org/10.3892/etm.2013.1173
Pages: 611-615

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Circulating levels of leptin are increased in obesity and have been proposed to contribute to the development of hypertension in obese individuals. Four cardiac hormones, specifically, vessel dilator, long‑acting natriuretic peptide (LANP), kaliuretic peptide and atrial natriuretic peptide (ANP), have blood pressure‑lowering properties and correlate with the presence of hypertension in obesity. The objective of this study was to determine whether one or more of these cardiac hormones was able to decrease the levels of leptin in the hypothalamus, an area of the brain that has been demonstrated to synthesize more than 40% of leptin in the circulation. The effects of these four cardiac hormones on leptin were examined using dose‑response curves in the rat hypothalamus, which synthesizes leptin. Vessel dilator, LANP, kaliuretic peptide and ANP maximally decreased the levels of leptin in hypothalamic cells by 79, 76, 80 and 62%, respectively (P<0.0001 for each). The cardiac hormones decreased leptin levels over a concentration range of 100 pM to 10 µM, with the most significant reductions in leptin levels occurring when the concentrations of the hormones were at micromolar levels. The results of the study suggest that the four cardiac hormones lead to significant reductions in hypothalamic leptin levels, which may be an important mechanism for alleviating leptin‑induced hypertension in obesity.

View Figures

View References

1.	Kshatriya S, Lui K, Salah A, Szombathy T, Freeman RH, Reams GP, Spear RM and Villarreal D: Obesity hypertension: the regulatory role of leptin. Int J Hypertens. 2011:2706242011. View Article : Google Scholar : PubMed/NCBI
2.	Lönnqvist F: The obese (ob) gene and its product leptin - a new route toward obesity treatment in man? QJ Med. 89:327–332. 1996.PubMed/NCBI
3.	Misra A and Garg A: Leptin, its receptor and obesity. J Investig Med. 44:540–548. 1996.PubMed/NCBI
4.	Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, et al: Identification and expression cloning of a leptin receptor, OB-R. Cell. 83:1263–1271. 1995. View Article : Google Scholar : PubMed/NCBI
5.	Esler M, Vaz M, Collier G, Nester P, Jennings G, Kaye D, Seals D and Lambert G: Leptin in human plasma is derived in part from the brain, and cleared by the kidneys. Lancet. 351:879–880. 1998. View Article : Google Scholar : PubMed/NCBI
6.	Eikelis N, Lambert G, Wiesner G, Kaye D, Schlaich M, Morris M, Hastings J, Socratous F and Esler M: Extra-adipocyte leptin release in human obesity and its relation to sympathoadrenal function. Am J Physiol Endocrinol Metab. 286:E774–E752. 2004. View Article : Google Scholar : PubMed/NCBI
7.	Morash B, Li A, Murphy PR, Wilkinson M and Ur E: Leptin gene expression in the brain and pituitary gland. Endocrinology. 140:5995–5998. 1999. View Article : Google Scholar : PubMed/NCBI
8.	Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL and Caro JF: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New Engl J Med. 334:292–295. 1996. View Article : Google Scholar : PubMed/NCBI
9.	Garrison RJ, Kannel WB, Stokes J III and Castelli WP: Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med. 16:235–251. 1987. View Article : Google Scholar : PubMed/NCBI
10.	Wofford MR and Hall JE: Pathophysiology and treatment of obesity hypertension. Curr Pharm Des. 10:3621–3637. 2004. View Article : Google Scholar : PubMed/NCBI
11.	Shek EW, Brands MW and Hall JE: Chronic leptin infusion increases arterial pressure. Hypertension. 31:409–414. 1998. View Article : Google Scholar : PubMed/NCBI
12.	Yuan K, Yu J, Shah A, Gao S, Kim SY, Kim SZ, Park BH and Kim SH: Leptin reduces plasma ANP level via nitric oxide-dependent mechanism. Am J Physiol Regul Integr Comp Physiol. 298:R1007–R1016. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Huang F, Xiong X, Wang H, You S and Zeng H: Leptin-induced vascular smooth muscle cell proliferation via regulating cell cycle, activating ERK1/2 and NF-kappaB. Acta Biochim Biophys Sin (Shanghai). 42:325–331. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Sengenès C, Berlan M, De Glisezinski I, Lafontan M and Galitzky J: Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 14:1345–1351. 2000.
15.	Sengenès C, Bouloumie A, Hauner H, Berlan M, Busse R, Lafontan M and Galitzky J: Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem. 278:48617–48626. 2003.PubMed/NCBI
16.	Moro CC, Galitzky J, Sengenès C, Crampes F, Lafontan M and Berlan M: Functional and pharmacological characterization of the natriuretic peptide-dependent lipolytic pathway in human fat cells. J Pharmacol Exp Ther. 308:984–992. 2004. View Article : Google Scholar : PubMed/NCBI
17.	Uehlinger DE, Weidemann P, Gnädinger MP, Hasler L, Bachmann C, Shaw S, Hellmüller B and Lang RE: Increase in circulating insulin induced by atrial natriuretic peptide in normal humans. J Cardiovasc Pharmacol. 8:1122–1129. 1986. View Article : Google Scholar : PubMed/NCBI
18.	Galitzky J, Sengenès C, Thalamus C, Marques MA, Senard JM, Lafontan M and Berlan M: The lipid-mobilizing effect of atrial natriuretic peptide is unrelated to sympathetic nervous system activation or obesity in young men. J Lipid Res. 42:536–544. 2001.
19.	Birkenfeld AL, Boschmann M, Moro C, Adams F, Heusser K, Franke G, Berlan M, Luft FC, Lafontan M and Jordan J: Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab. 90:3622–3628. 2005. View Article : Google Scholar : PubMed/NCBI
20.	Vesely DL: Natriuretic hormones. Seldin and Giebisch’s, The Kidney: Physiology and Pathophysiology. Alpern RJ, Moe OW and Caplan M: 5th edition. Elsevier/North - Holland Biomedical Press; Amsterdam: pp. 1241–1281. 2013
21.	Martin DR, Pevahouse JB, Trigg DJ, Vesely DL and Buerket JE: Three peptides from the ANF prohormone NH₂-terminus are natriuretic and/or kaliuretic. Am J Physiol. 258:F1401–F1408. 1990.PubMed/NCBI
22.	Gunning ME, Brady HR, Otuechere G, Brenner BM and Ziedel ML: Atrial natriuretic peptide(31–67) inhibits Na⁺ transport in rabbit inner medullary collecting duct cells. Role of prostaglandin E2. J Clin Invest. 89:1411–1417. 1992.
23.	Benjamin BA and Peterson TV: Effects of proANF-(31–67) on sodium excretion in conscious monkeys. Am J Physiol. 269:R1351–R1355. 1995.
24.	Zeidel ML: Regulation of collecting duct Na⁺ reabsorption by ANP 31-67. Clin Exp Pharmacol Physiol. 22:121–124. 1995. View Article : Google Scholar
25.	Villarreal D, Reams GP, Taraben A and Freeman RH: Hemodynamic and renal effects of proANF31-67 in hypertensive rats. Proc Soc Exp Biol Med. 221:166–170. 1999. View Article : Google Scholar : PubMed/NCBI
26.	Dietz JR, Scott DY, Landon CS and Nazian SJ: Evidence supporting a physiological role for proANP-(1–30) in the regulation of renal excretion. Am J Physiol Regul Integr Comp Physiol. 280:R1510–R1517. 2001.PubMed/NCBI
27.	Vesely DL, Douglass MA, Dietz JR, Gower WR Jr, McCormick MT, Rodriguez-Paz G and Schocken DD: Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis and/or kaliuresis in humans. Circulation. 90:1129–1140. 1994. View Article : Google Scholar
28.	Vesely DL, Douglass MA, Dietz JR, Giordano AT, McCormick MT, Rodriguez-Paz G and Schocken DD: Negative feedback of atrial natriuretic peptides. J Clin Endocrinol Metab. 78:1128–1134. 1994.PubMed/NCBI
29.	Vesely DL, Dietz JR, Parks JR, Baig M, McCormick MT, Cintron G and Schocken DD: Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation. 98:323–329. 1998. View Article : Google Scholar
30.	Sugarawa A, Nakao K, Sakamoto M, Morii N, Yamada T, Itoh H, Shiono S and Imura H: Plasma concentration of atrial natriuretic polypeptide in essential hypertension. Lancet. 2:1426–1427. 1985. View Article : Google Scholar
31.	Arendt R, Gerbes A, Ritter D, Stangl E and Zähringer J: Atrial natriuretic factors in plasma of patients with arterial hypertension, heart failure or cirrhosis of the liver. J Hypertens Suppl. 4:S131–S135. 1986.PubMed/NCBI
32.	McMurray RW Jr and Vesely DL: Weight reduction decreases atrial natriuretic factor and blood pressure in obese patients. Metabolism. 38:1231–1237. 1989. View Article : Google Scholar : PubMed/NCBI
33.	McMurray RW Jr and Vesely DL: Weight reduction decreases the circulating concentration of the N-terminus of the ANF prohormone. Am J Med Sci. 303:2–8. 1992. View Article : Google Scholar : PubMed/NCBI
34.	McMurray RW Jr and Vesely DL: Calorie-restricted weight reduction, blood pressure, and atrial natriuretic peptides. Nutrition. 9:178–182. 1993.PubMed/NCBI
35.	Cao R, Brakenhielm E, Wahlestedt C, Thyberg J and Cao Y: Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci USA. 98:6390–6395. 2001. View Article : Google Scholar : PubMed/NCBI
36.	Nguyen JP, Frost CD, Lane ML, Skelton lv WP, Skelton M and Vesely DL: Novel dual inhibitors of vascular endothelial growth factor and VEGFR2 receptor. Eur J Clin Invest. 42:1061–1067. 2012. View Article : Google Scholar : PubMed/NCBI
37.	Fain JN, Kanu A, Bahouth SW, Gowan GS and Lloyd Hiler M: Inhibition of leptin release by atrial natriuretic peptide (ANP) in human adipocytes. Biochem Pharmacol. 65:1883–1888. 2003. View Article : Google Scholar : PubMed/NCBI
38.	Sarzani R, Dessì-Fulgheri P, Paci VM, Espinosa E and Rappelli A: Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest. 19:581–585. 1996. View Article : Google Scholar : PubMed/NCBI
39.	Vesely DL: Peptides from the N-terminus of the atrial natriuretic factor prohormone enhance guanylate cyclase activity and increase cyclic GMP levels in a wide variety of tissues. Mol Cell Biochem. 109:43–50. 1992. View Article : Google Scholar : PubMed/NCBI
40.	Jensen MD, Haymond MW, Rizza RA, Cryer PE and Miles JM: Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest. 80:1168–1173. 1989. View Article : Google Scholar : PubMed/NCBI
41.	Bougnères P, Stunff CL, Pecqueur C, Pinglier E, Adnot P and Ricquier D: In vivo resistance of lipolysis to epinephrine. A new feature of childhood onset obesity. J Clin Invest. 99:2568–2573. 1997.PubMed/NCBI